Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine.
Continuing experience with oxcarbazepine has shown that the drug tends to be less sedative than carbamazepine and at least as potent as an anticonvulsant but much more likely to cause hyponatraemia. The behaviour of the clearance of oxcarbazepine over a period of 3 months raises the possibility that the drug may not be as active an inducer of drug metabolism as is carbamazepine.
Dickinson
R G
RG
Department of Medicine, University of Queensland.
Hooper
W D
WD
Pendlebury
S C
SC
Moses
D
D
Eadie
M J
MJ
D000328:Adult; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D000078330:Oxcarbazepine
D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine